Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 5

Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: a 10-year experience

Authors Glen J Pearson, Kari L Olson, Nicole E Panich, Sumit R Majumdar, Ross T Tsuyuki, et al

Published 10 October 2008 Volume 2008:4(5) Pages 1127—1135

DOI https://doi.org/10.2147/VHRM.S3748

Review by Single-blind

Peer reviewer comments 2

Glen J Pearson1,5, Kari L Olson6, Nicole E Panich1, Sumit R Majumdar2,5, Ross T Tsuyuki1,4, Dawna M Gilchrist2,5, Ali Damani4, Gordon A Francis3,5

The MILLARR Study (Maintenance of Improved Lipid Levels Following Attendance at a Cardiovascular Risk Reduction Clinic) 1Department of Medicine, Divisions of Cardiology; 2General Internal Medicine; 3Endocrinology and Metabolism; Faculty of Pharmacy and Pharmaceutical Sciences; 4University of Alberta, Edmonton, Alberta, Canada; 5Cardiovascular Risk Reduction Clinic (CRRC), University of Alberta Hospital, Edmonton, Alberta, Canada; 6University of Colorado Health Sciences Center, Denver, Colorado, USA; 7Family Medicine (Private Practice), Calgary, Alberta, Canada

Background: Specialty cardiovascular risk reduction clinics (CRRC) increase the proportion of patients attaining recommended lipid targets; however, it is not known if the benefits are sustained after discharge. We evaluated the impact of a CRRC on lipid levels and assessed the long-term effect of a CRRC in maintaining improved lipid levels following discharge.

Methods: The medical records of consecutive dyslipidemic patients discharged >6 months from a tertiary hospital CRRC from January 1991 to January 2001 were retrospectively reviewed. The primary outcome was the change in patients’ lipid levels between the final CRRC visit and the most recent primary care follow-up. A worst-case analysis was conducted to evaluate the potential impact of the patients in whom the follow-up lipid profiles post-discharge from the CRRC were not obtained.

Results: Within the CRRC (median follow-up = 1.28 years in 1064 patients), we observed statistically significant improvements in all lipid parameters. In the 411 patients for whom post-discharge lipid profiles were available (median follow-up = 2.41 years), there were no significant differences observed in low-density lipoprotein-cholesterol, total cholesterol (TC), or triglycerides since CRRC discharge; however, there were small improvements in high-density lipoprotein-cholesterol (HDL-C) and TC:HDL ratio (p < 0.05 for both). The unadjusted worst-case analysis (653 patients with no follow-up lipid profiles) demonstrated statistically significant worsening of all lipid parameters between CRRC discharge and the most recent follow-up. However, when the change in lipid parameters between the baseline and the most recent follow-up was assessed in this analysis, the changes in all lipid parameters were significantly improved (p < 0.05).

Conclusions: This study demonstrates that a CRRC can improve lipid levels and suggests that these benefits are sustained once patients are returned to the care of their primary physician.

Keywords: cardiovascular risk factors, dyslipidemia, outcomes, pharmacotherapy, secondary prevention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease

Herrán E, Requejo C, Ruiz-Ortega JA, Aristieta A, Igartua M, Bengoetxea H, Ugedo L, Pedraz JL, Lafuente JV, Hernández RM

International Journal of Nanomedicine 2014, 9:2677-2687

Published Date: 27 May 2014

Fabrication of nanoadjuvant with poly-e-caprolactone (PCL) for developing a single-shot vaccine providing prolonged immunity

Prashant CK, Bhat M, Srivastava SK, Saxena A, Kumar M, Singh A, Samim M, Ahmad FJ, Dinda AK

International Journal of Nanomedicine 2014, 9:937-950

Published Date: 12 February 2014

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin

Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS

Vascular Health and Risk Management 2013, 9:273-282

Published Date: 29 May 2013

The role of cholesterol-sphingomyelin membrane nanodomains in the stability of intercellular membrane nanotubes

Lokar M, Kabaso D, Resnik N, Sepčić K, Kralj-Iglič V, Veranič P, Zorec R, Iglič A

International Journal of Nanomedicine 2012, 7:1891-1902

Published Date: 10 April 2012

ST segment depression in hypertensive patients: A comparison of exercise test versus Holter ECG

Sakir Uen, Rolf Fimmers, Burkhard Weisser, Osman Balta, Georg Nickenig, Thomas Mengden

Vascular Health and Risk Management 2008, 4:1073-1080

Published Date: 10 October 2008

Early seizures in patients with acute stroke: Frequency, predictive factors, and effect on clinical outcome

Andrea Alberti, Maurizio Paciaroni, Valeria Caso, Michele Venti, Francesco Palmerini, Giancarlo Agnelli

Vascular Health and Risk Management 2008, 4:715-720

Published Date: 6 June 2008

Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: Implication in the pathogenesis of Alzheimer’s disease

Gjumrakch Aliev, Eldar Gasimov, Mark E Obrenovich, Kathryn Fischbach, Justin C Shenk, et al

Vascular Health and Risk Management 2008, 4:721-730

Published Date: 6 June 2008

Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients’ risk level

Daria Roccatagliata, Fausto Avanzini, Lara Monesi, Vittorio Caimi, Davide Lauri, Paolo Longoni, Roberto Marchioli, Massimo Tombesi, Gianni Tognoni, Maria Carla Roncaglioni, on behalf of the Collaborative Group Risk and Prevention Study

Vascular Health and Risk Management 2006, 2:507-514

Published Date: 15 December 2006

Society News: ISVH – A multi-disciplinary society ||FREE PAPER||

Roland Asmar

Vascular Health and Risk Management 2006, 2:325-326

Published Date: 15 December 2006